Moderna Reports Q4 Loss of $2.91 per Share Amid Vaccine Demand Decline

Moderna Inc. reported a significant fourth-quarter loss of $2.91 per share, exceeding analysts' expectations of a $2.68 loss, primarily due to a 66% drop in revenue to $966 million, down from $2.81 billion a year ago. The decline was attributed to the earlier launch of its updated COVID-19 vaccine, which shifted sales to the third quarter, along with lower international sales as advance purchase agreements phased out. The company reported $923 million in Spikevax sales for the quarter, contributing to a total of $3.1 billion for the year. Additionally, Moderna's cost of sales was markedly lower, reflecting ongoing cost-cutting measures. Despite the challenging financial landscape, Moderna maintains its 2025 revenue outlook between $1.5 billion and $2.5 billion. The company is also focusing on new product development, with plans for potential approvals for its RSV vaccine later this year.